Pancreas · 2025
Somatostatin Analogs Versus Active Surveillance in Small Pancreatic Neuroendocrine Tumors.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maratta Maria Grazia, Chiloiro Sabrina, Raia Salvatore, Maiorano Brigida A, Horn Guido, Brizi Maria Gabriella, Rufini Vittoria, Giancipoli Romina Grazia, De Marinis Laura, Bianchi Antonio, Pontecorvi Alfredo, Schinzari Giovanni, Inzani Frediano, Tortora Giampaolo, Rindi Guido
Аннотация
OBJECTIVES: The best strategy for nonfunctioning, sporadic, G1-G2 pancreatic neuroendocrine tumors ≤2 cm is unknown. An active surveillance is usually recommended. The PROMID and the CLARINET studies proved the value of somatostatin analog (SSA) treatment in advanced gastro-entero-pancreatic neuroendocrine tumors. The aim of this study is to assess the value of SSA in pancreatic NET (PanNET) ≤ 2 cm.
MATERIALS AND METHODS: We retrospectively collected data from 72 patients with sporadic nonfunctioning G1-G2 PanNETs ≤ 2 cm, which were either treated with somatostatin analogs (n = 31) or underwent active surveillance (n = 41) at our institution.
RESULTS: At a median follow-up of 53.7 months, the median progression-free survival was not reached in the treatment group versus an estimated progression-free survival of 85 months in the control group (hazard ratio, 0.11; P = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group. Additionally, in the group of patients treated with somatostatin analogs, the response rate was 16.1% with 1 complete response.
CONCLUSIONS: Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogs in patients with sporadic, nonfunctionating G1-G2 PanNETs ≤ 2-cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness.
MATERIALS AND METHODS: We retrospectively collected data from 72 patients with sporadic nonfunctioning G1-G2 PanNETs ≤ 2 cm, which were either treated with somatostatin analogs (n = 31) or underwent active surveillance (n = 41) at our institution.
RESULTS: At a median follow-up of 53.7 months, the median progression-free survival was not reached in the treatment group versus an estimated progression-free survival of 85 months in the control group (hazard ratio, 0.11; P = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group. Additionally, in the group of patients treated with somatostatin analogs, the response rate was 16.1% with 1 complete response.
CONCLUSIONS: Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogs in patients with sporadic, nonfunctionating G1-G2 PanNETs ≤ 2-cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness.